Background:
The HER2 (human epidermal growth factor receptor-2) Ile655Val (rs1136201) genetic polymorphism can alter the receptor structure and its autoactivation, which can modify the signal transduction and, consequently, the cell cycle regulation. For this reason, this polymorphism has been extensively investigated as a candidate marker for breast cancer (BC). In this context, the aim of this study was to evaluate the possible influence of HER2 Ile655Val in BC susceptibility and prognostic factors in a Brazilian population.
Methods:
Polymorphism genotype was assessed through RFLP-PCR in 107 BC patients with clinicopathological data available and in 150 women with no evidence of neoplasia and with no familial history of BC as control group. Association between this polymorphism and BC susceptibility and clinical parameters was evaluated through odds ratio (OR) and chi-squared or Fisher's exact test, respectively.
Results: A significant negative association between valine allele and BC susceptibility in dominant model was found (OR 0.5; 95% CI 0.27-0.93, P = .036). No significant association was found in relation to BC clinicopathological features (tumor size, lymph nodes commitment, histological grade, HER2 overexpression, hormonal receptors, p53, and Ki-67).
Conclusion: Although this polymorphism did not demonstrate potential as a prognos-
tic marker, it may be a suitable susceptibility marker for BC.
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| RESULTS
| Sample characterization
The average age for breast cancer patients was 56.4 years. The highest incidence of BC was observed between 40 and 49 years. The average age for the control group was 50.5 years.
Most patients had tumor in stage II or III (82.75%). About 59.8% of the patients had tumor size between 1.5 and 3.0 cm, and the average tumor size was 3.10 cm. Additionally, 64.6% of patients were classified as HER2 negative, 43.26% were classified as luminal, and 8.65% were classified as triple negative (TN) subtypes.
| HER2 Ile655Val polymorphism and BC susceptibility
To confirm the genotypes obtained by RFLP-PCR, DNA sequencing of 3 amplified PCR fragments was performed, as shown in Figure 1 .
Genotype distribution and association analyses are shown in Table 1 .
A negative association in relation to BC susceptibility was observed, in T A B L E 1 Case-control association study for Ile655Val polymorphism in BC patients and neoplasia-free women frequency was 9.09% (P = .04). Val allele was significantly more frequent in our population than in all African populations (Val frequency = 0.08%, P < .0001 in pooled analysis), in which this allele was extremely rare or absent (for the majority of populations in African continent). Val allele frequency was significantly smaller in our population than in all European populations (Val frequency = 24.55%; P = .001 in pooled analysis), except for Italian population from Toscana (Val frequency = 12.5%, P = .3).
| HER2 Ile655Val polymorphism and BC clinical presentation
There was no significant association between Ile655Val in the dominant model of analysis and any clinicopathological parameter tested ( Possible associations between HER2 Ile655Val and clinicopathological parameters were also tested considering only HER2-positive BCs, but no statistically significant association was found. In contrast, a study conducted by Baxter and Campbell, 19 which examined British BC patients with an average age of 38 years, found no significant association, leading to the conclusion that this polymorphism has a large variation between different ethnic groups. In our study, we did not find differences in Val allele distribution among age groups. Furthermore, in our samples, patients below 40 years did not exhibit this allele, hampering the ability to study the possible association between this polymorphism and early onset BC (Table 2) .
| DISCUSSION
Based on other studies, this one included, we can observe that there is great variation in genetic markers among different populations. Some common polymorphism frequencies in Asian populations seem to be completely different from those that occur in European populations. Thus, the susceptibility to cancer depends on ethnicity and environmental risk factors, whose population is exposed.
This probably explains why the present results, based on a Brazilian who showed no association between this polymorphism and clinicopathological features in a cohort of Chinese BC patients.
However, in the same work, the authors showed that Val allele was an important prognostic factor in HER2-positive BCs, indicating a more aggressive tumor phenotype with worst outcome when treated with conventional adjuvant chemotherapy, but more favorable response to the targeted therapy with trastuzumab. 20 This highlights the clinical importance of studying this polymorphism in BC patients worldwide.
In conclusion, the present study suggests that HER2 Ile655Val polymorphism may be a candidate marker for BC susceptibility.
Further studies involving larger samples are necessary to validate its potential as a BC marker, emphasizing that its impact on disease susceptibility may diverge between different populations around the world. Although no association with prognostic factors were found in the present work, literature highlights the need to delineate prospective studies in different populations to evaluate the real potential prognostic role for this polymorphism, especially in HER2-positive BCs.
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